Canada · Delayed Price · Currency is CAD Delivra Health Brands Earnings Call Transcripts
Fiscal Year 2025
-
Revenue grew 80% year-over-year with strong gross margins and positive adjusted EBITDA for the third year. Distribution and innovation expanded across North America and internationally, with a robust balance sheet supporting future growth.
-
A successful turnaround has led to strong margin and EBITDA improvements, with consistent revenue growth and reduced SG&A. Market share is robust in key segments, and expansion is underway in new channels and geographies. Expect further customer growth, innovation, and global reach.
-
Q2 net sales rose 34% year-over-year to CAD 2.8 million, driven by Dream Water growth and expanded marketing. Gross margin for H1 was 49%, with a net loss of CAD 176,000, reflecting increased investment in innovation and market expansion.
Fiscal Year 2024
-
Delivered a strong fiscal 2024 with 26% revenue growth, positive Adjusted EBITDA, and expanded margins, driven by operational efficiency and brand strength. Strategic focus on innovation, geographic expansion, and disciplined financial management positions the company for sustainable growth.